US Patent 9133271 Anti-DLL3 antibody drug conjugates and methods of use
Patent 9133271 was granted and assigned to Stemcentrx, Inc. on September, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+209 characters)
Article
Patent abstract
Provide are novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat recurrent tumors and to reduce or inhibit tumor recurrence in a subject.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09133271 Anti-DLL3 antibody drug conjugates and methods of use US Patent 9133271 Anti-DLL3 antibody drug conjugates and methods of use
Infobox
Patent Number
09133271
Patent Number
9133271
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09133271 Anti-DLL3 antibody drug conjugates and methods of use
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09133271
Date of patent
September 15, 2015
Patent application number
14742576
Date Filed
June 17, 2015
Patent primary examiner
Find more entities like US Patent 9133271 Anti-DLL3 antibody drug conjugates and methods of use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
